Trump backlash adds new risks to the stocks the government owns

Government equity-stake moves tied to the Trump administration have driven outsized stock runs (Intel +300% y/y; MP Materials +87% since a $400M DoD equity investment; Trilogy Metals +73%), but gains have since reversed sharply (Trilogy: $10.60 high to $3.62; MP Materials: down ~27% y/y; Intel: -37% since the Apple semiconductor announcement). With Democrats likely to gain congressional control, strategists flag rising scrutiny, hearings, subpoenas, and brand/share-price risk, alongside a growing legal overhang—Intel faces a shareholder suit challenging whether the Chips Act authorizes Commerce to demand equity as a grant condition, with Lutnick seeking dismissal. Market impact is potentially sector-moving because adverse court rulings could undermine broader Chips Act equity investments.

Analysis

The market is treating these stakes like a durable policy backstop, but the cleaner read is that they are a tradable sentiment premium layered on top of already-volatile fundamentals. That premium is most fragile in names where the equity bid is doing more work than cash flow, which is why INTC remains the highest-beta expression: if the court path weakens the government’s authority, the stock can de-rate quickly even if operating execution stays intact. By contrast, a name like AAPL is only a peripheral beneficiary; the real sensitivity is in companies whose capital structure and valuation now depend on perceived federal sponsorship.

Second-order effects are broader than the individual tickers. If a court or Congress constrains the model, future CHIPS/critical-minerals awards should carry a lower political multiple, making it harder for GFS, IBM, MP and any follow-on recipients to monetize “government as anchor customer” narratives. That would also improve the relative position of non-sponsored incumbents in semis and industrials, because the market would stop paying up for policy optionality and refocus on self-funded growth. The flip side is that a successful legal defense would reinforce a new playbook where investors front-run federal backing, which would extend the bubble in politically connected microcaps.

Timing matters: midterm scrutiny is a 1-3 month overhang, but the litigation is the real 6-18 month catalyst because it can invalidate the entire framework rather than just pressure headlines. The key falsifier for the short thesis is a court dismissal or a clear appellate signal that the Commerce Department’s equity authority survives; that would likely re-ignite the basket and force a momentum squeeze. On the other hand, any hearing that uncovers weak process or governance optics should be enough to compress multiples before final judgment.

The contrarian view is that the market may be underestimating how quickly a ‘political put’ can become a governance discount. Investors are paying for upside convexity from government support, but once that support becomes litigable, the same mechanism works in reverse: every headline increases the probability of dilution, restrictions, or judicial unwind. In that regime, the best risk-adjusted trade is not to short the concept broadly, but to target the most litigation-sensitive and least fundamentally self-sustaining names.

Key Decisions for Investors

• Buy INTC 3-6 month put spreads on strength; thesis is a legal/governance multiple reset rather than an operating collapse. Risk/reward is attractive if the stock continues to trade on the federal backstop premium, but cover immediately if the suit is dismissed or appeals turn favorable.
• Relative-value: long SOXX / short INTC for 1-3 months. This isolates the company-specific political overhang while keeping exposure to the broader AI/semis cycle; the trade works if the market begins separating real semiconductor earnings power from policy-driven support.
• Fade MP on rally attempts via small outright short or put spreads, not size. The trade is tactical only: the stock is vulnerable to a momentum unwind, but borrow/short-squeeze risk argues for options rather than cash short.
• Watch GFS and IBM as a delayed second-order short candidate only if the court case broadens into a CHIPS-authority issue. If that happens, expect a basket de-rating across government-linked beneficiaries over 1-3 months; if not, leave them alone.
• No trade in AAPL unless new disclosure shows it is becoming materially tied to the program. For now it is a sentiment bystander, not a fundamental beneficiary, so the better expression is to own the broader semi cycle and avoid the political names.